Exploring Quinolone Scaffold: Unravelling the Chemistry of Anticancer Drug Design

Vishal Sharma1, Rina Das1, Dinesh Kumar Mehta1

  • 1MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Hr 133207, India.

Insights

This review highlights quinolone derivatives as promising anti-cancer agents. Recent synthetic methods and structure-activity relationships are discussed for developing new drug candidates against resistant cancers.

Area of Science:

  • Medicinal Chemistry
  • Drug Discovery
  • Organic Synthesis

Background:

  • Cancer poses a significant global health burden, exacerbated by increasing drug resistance.
  • Quinolone derivatives exhibit notable pharmacological activities, making them attractive for anti-cancer drug development.

Purpose of the Study:

  • To review recent synthetic approaches for quinolone derivatives.
  • To outline potent quinolone derivatives based on structure-activity relationships.
  • To discuss advancements in the synthesis of novel anti-cancer drug candidates.

Main Methods:

  • Exploration of diverse synthetic strategies including one-pot synthesis, post-Ugi-transformation, and catalyst-based methods.
  • Analysis of structure-activity relationships for quinolone derivatives.
  • Review of recent literature on quinolone-based anti-cancer agents.

Main Results:

  • Various synthetic protocols have been successfully employed to generate quinolone derivatives.
  • Reported quinolone molecules demonstrate significant anti-cancer activities.
  • Recent advancements include enzyme-based and nano-catalyst based synthetic procedures.

Conclusions:

  • Quinolone derivatives represent a vital class of compounds for developing novel anti-cancer therapies.
  • Continued research into synthetic modifications and structure-activity relationships is crucial for optimizing anti-cancer efficacy.
  • The development of efficient and innovative synthetic methods is key to advancing quinolone-based drug discovery.

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.2K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
17.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K